Fresenius Medical Care AG (FMCQF)
| Market Cap | 12.21B -17.0% |
| Revenue (ttm) | 23.05B +1.5% |
| Net Income | 1.15B +81.9% |
| EPS | 3.94 +83.6% |
| Shares Out | n/a |
| PE Ratio | 10.63 |
| Forward PE | 9.17 |
| Dividend | 1.62 (3.67%) |
| Ex-Dividend Date | May 23, 2025 |
| Volume | 127 |
| Average Volume | 4,523 |
| Open | 44.25 |
| Previous Close | 49.21 |
| Day's Range | 44.25 - 44.25 |
| 52-Week Range | 44.25 - 61.84 |
| Beta | 0.85 |
| RSI | 39.62 |
| Earnings Date | May 5, 2026 |
About Fresenius Medical Care AG
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, the United States, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospital... [Read more]
Financial Performance
In 2025, Fresenius Medical Care AG's revenue was 19.63 billion, an increase of 1.51% compared to the previous year's 19.34 billion. Earnings were 978.37 million, an increase of 81.88%.
Financial numbers in EUR Financial StatementsNews
Fresenius Medical Care delivers 27% earnings growth in 2025 and reaches upper end of its financial outlook; margin within 2025 mid-term target band
Strong organic revenue growth1 in 2025 of 8% driven by all operating segments Driven by an exceptional Q4, full year operating income2 growth of 27% reached top end of financial outlook, resulting in ...
Fresenius Medical Care Shares Drop After Outlook, U.S. Performance Underwhelms
Shares in the dialysis specialist were down 7.1% in European midday trade, with the decline erasing gains since the start of 2026.
Fresenius Medical Care's operating profit surges in Q4
Fresenius Medical Care reported a sharp rise in fourth‑quarter operating income on Tuesday, helped by accelerating cost savings and favourable reimbursement effects.
Fresenius Medical Care accelerates the second tranche of its EUR 1 billion share buyback program with around EUR 415 million repurchase planned
The second tranche of the share buyback is expected to be executed by May 8, 2026 The share buyback program with a total volume of EUR 1 billion is expected to be completed in less than a year, signif...
Fresenius Medical Care appoints Charles Hugh-Jones as Global Chief Medical Officer and member of the Management Board
Effective January 1, 2026, Charles Hugh-Jones will join the Management Board as Global Chief Medical Officer As part of a planned transition Franklin W. Maddux will retire by year end BAD HOMBURG, Ger...
Fresenius Medical Care further accelerates organic revenue development and achieves an inflection in earnings growth, delivering 28% operating income growth in the third quarter of 2025
Strong organic revenue growth1 of 10% driven by all operating segments Positive U.S. same market treatment growth of 0.1 % in line with expectations Accelerated operating income2 growth of 28% at cons...
Fresenius Medical Care beats quarterly profit estimates helped by cost cuts
Fresenius Medical Care reported a third-quarter operating income that exceeded analysts' expectations on Tuesday, in a sign that the dialysis specialist's cost-cutting measures were beginning to take ...
Fresenius Medical Care highlights real-world advances in hemodiafiltration and AI at ASN Kidney Week 2025
Fresenius Medical Care researchers will present multiple abstracts that demonstrate proven, real-world benefits of hemodiafiltration (HDF), with one accepted as an oral presentation. Oral presentation...
Fresenius Medical Care appoints Joseph Turk as new Management Board Member for Care Enablement
Effective January 1, 2026, Joseph Turk will join the Management Board as Chief Executive Officer of the global operating segment Care Enablement As part of a planned transition Dr. Katarzyna Mazur-Hof...
Fresenius Medical Care advances its FME Reignite strategy by increasing ownership in its Value-Based Care asset and appointing a new leader for the operating segment
Fresenius Medical Care invests EUR 312 million and successfully closes a share purchase agreement with all non-physician investors in Interwell Health (IWH), accelerating the timeline originally set d...
Fresenius Medical Care announces first tranche of its share buyback program of up to EUR 600 million as part of its new capital allocation framework
Total volume of the initial share buyback is up to EUR 1 billion over two years Share buyback to take place until August 10, 2027 BAD HOMBURG, Germany , Aug. 11, 2025 /PRNewswire/ -- Fresenius Medical...
Fresenius Medical Care delivers strong organic revenue growth and double-digit operating income growth in the second quarter of 2025
Strong organic revenue growth1 of 7% driven by all operating segments Stable U.S. same market treatment development driven by accelerating patient inflow FME25+ savings of EUR 58 million contributed t...
$6.3 Trillion Outpatient Clinics Markets, 2021-2024 & 2025-2029 | Profiles of Leading Players - Johns Hopkins Medicine, Mayo Clinic, MD Anderson Cancer Center, Apollo Hospital, and Fresenius Medical
Explore the latest report on the global outpatient clinics market, analyzing trends, revenue, and forecasts from 2023 to 2029. This comprehensive study covers services, specialty, regional insights, a...
Fresenius Medical Care Collaborates with Coordination of National Institutes of Health and Specialty Hospital to Extend Access to Innovative Dialysis Therapy in Mexico
High-Volume Hemodiafiltration is used for the first time in seven out of 10 CCINSHAE centers in Mexico In Mexico, 240 CCINSHAE patients are now being treated; more than 410 regular patients also treat...
Fresenius Medical Care Launches Value-Based Care Segment, Eyes Growth Through Innovation, Efficiency
Fresenius Medical Care AG FMS on Tuesday introduced a strategic roadmap — FME Reignite — aimed at revitalizing its core business, driving innovation and reshaping its organizational culture.
Fresenius Medical Care CEO Says Company Could Benefit From Obesity Drugs
EXCLUSIVE: The dialysis company believes the impact of the treatments on its own performance will be ‘neutral to positive' rather than negative.
Fresenius Medical Care Launches its Strategy FME Reignite with increased Profitability Aspirations, and a New Capital Allocation Framework to further enhance Value Creation
FME Reignite sets the ambition to lead kidney care through exceptional patient care and innovation The Company will set the new standard of care in the U.S. with the introduction of the 5008X dialysis...
Fresenius Medical Care announces 1 bln euros share buyback programme
The world's largest dialysis specialist Fresenius Medical Care said, ahead of its capital markets day on Tuesday, that it plans to embark on a 1 billion euros ($1.16 billion) share buyback programme.
5 Stocks To Ride The German Market Rally
Stocks in the United States have struggled to regain their February all-time highs amid the tariff uncertainty. In fact, the S&P 500 remains one of the worst-performing major stock indices in the deve...
Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X™ CAREsystem, Achieves Key Milestones in Efforts to Introduce High-Volume Hemodiafiltration Dialysis Therapy to Individuals with Kidney Disease in the U.S.
Updated 5008X CAREsystem with Additional Features Receives FDA 510(k) Clearance Company announces first wave of Fresenius Kidney Care clinics in the U.S. to begin offering high-volume hemodiafiltrati...
Fresenius Medical Care presents its new research and innovation for kidney care at European Renal Association Congress 2025
Key abstract presentations showcase significant advancements in clinical care, artificial intelligence, and fluid management, demonstrating Fresenius Medical Care's commitment to improving patient out...
Fresenius Medical Care Annual General Meeting: Strong Performance Against Its Strategic Plan Results in Highest Dividend per Share in Its History
Shareholders approved the proposed dividend of 1.44 Euro per share, representing a 21 percent increase year-over-year and marking the highest dividend in the company's history Excellent progress in th...
Fresenius Medical Care starts 2025 with strong organic revenue and income growth
Strong organic revenue growth1 of 5% driven by Care Enablement and Care Delivery Stable U.S. same market treatment development despite impact from a severe flu season FME25 savings of EUR 68 million c...
Fresenius Medical Care tops market expectations in 1st quarter
World's largest dialysis specialist Fresenius Medical Care reported first-quarter results above analysts' expectations on Tuesday, as revenue grew organically in all its segments, it said.